Consolidated interim results for the fiscal year ending March 2027 showed revenue of 509,593 million yen (12.2% YoY increase), adjusted operating income of 95,833 million yen (89.6% YoY increase), and net income attributable to owners of parent of 52,146 million yen, marking substantial increases. Full-year forecasts for FY2027 were left unchanged, although the lower bound of revenue guidance was raised versus the prior forecast. Capital structure changed due to acquisitions including BioProtect Ltd. By segment, both Gastrointestinal Endoscopy Solutions and Surgical Intervention businesses achieved revenue and profit growth. Continued monitoring and mitigation of FDA-related risks and strengthening of third-party risk management are ongoing.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7733","jir_company_name":"Olympus Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-11-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/7733-20261110-01.pdf","jir_short_summary":"Consolidated interim results for the fiscal year ending March 2027 showed revenue of 509,593 million yen (12.2% YoY increase), adjusted operating income of 95,833 million yen (89.6% YoY increase), and net income attributable to owners of parent of 52,146 million yen, marking substantial increases. Full-year forecasts for FY2027 were left unchanged, although the lower bound of revenue guidance was raised versus the prior forecast. Capital structure changed due to acquisitions including BioProtect Ltd. By segment, both Gastrointestinal Endoscopy Solutions and Surgical Intervention businesses achieved revenue and profit growth. Continued monitoring and mitigation of FDA-related risks and strengthening of third-party risk management are ongoing.","jir_summary":"### Overview of Results\nOlympus achieved interim consolidated revenue of 509,593 million yen for the fiscal year ending March 2027, a 12.2% increase year-over-year. Operating income increased and adjusted operating income rose substantially to 95,833 million yen. By segment, Gastrointestinal Endoscopy Solutions and Surgical Intervention both remained strong. Foreign exchange effects contributed positively. Business combinations, including the acquisition of BioProtect Ltd., affected the capital structure. Ongoing measures are being taken to address FDA-related risks.\n\n### Outlook and Capital Policy\nThe Company's forecast for the fiscal year ending March 2027 remains unchanged from the most recently announced guidance, while reflecting progress that raised the lower bound of revenue. Foreign exchange is expected to contribute positively, while regulatory and quality risks related to the FDA and strengthened third-party risk management remain areas of focus. Optimization of the business portfolio, including effects from the acquisition of BioProtect, is positioned as a medium- to long-term growth driver. Share buyback and dividend policies are disclosed separately; this financial summary does not indicate any new material large-scale transactions regarding treasury stock acquisition\/disposition.","jir_financial_highlights":"Revenue: 509,593 (Year-over-Year 12.2% increase)\nAdjusted Operating Income: 95,833 (Year-over-Year 89.6% increase)\nNet Income Attributable to Owners of Parent (Interim): 52,146 (Year-over-Year 78.7% increase)\nTotal Assets: 1,521,887 (Compared with previous fiscal year-end -15,275)\nTreasury Stock: -85,473 (Compared with previous interim -58,842)","jir_category":"","jir_hashtags":"#Olympus, #Earnings, #InterimResults, #SegmentAnalysis","jir_key_figures":"Revenue: 509,593 million yen (Year-over-Year 12.2% increase)\nAdjusted Operating Income: 95,833 million yen (Year-over-Year 89.6% increase)\nNet Income Attributable to Owners of Parent (Interim): 52,146 million yen (Year-over-Year 78.7% increase)","jir_meta_title":"Olympus Corporation FY2027 Q2 Financial Summary | Revenue 509,593 million yen, Adjusted Operating Income 95,833 million yen","jir_meta_description":"Key points from Olympus Corporation's FY2027 Q2 financial summary. Revenue rose 12.2% YoY and adjusted operating income increased 89.6%. Financial position affected by the BioProtect acquisition. Outlook and risk factors summarized.","jir_og_title":"Olympus Corporation | FY2027 Q2 Financial Results: Revenue Growth and Substantial Increase in Adjusted Income","jir_og_description":"Olympus's interim results show revenue growth and a substantial rise in adjusted operating income. Reports on the impact of the BioProtect acquisition and progress on addressing FDA-related risks. See the financial summary for details.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2026-04\\\",\\\"2026-07\\\",\\\"2026-10\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[509593,_,_]}]}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2026-04\\\",\\\"2026-07\\\",\\\"2026-10\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[84962,_,_]}]}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Segment\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"Gastrointestinal Endoscopy Solutions\\\",\\\"Surgical Intervention\\\"],\\\"datasets\\\":[{\\\"data\\\":[509593-\u53ca\u3073\u88dc\u8db3,454350],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\"]}]}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Gross Margin Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"2026 Interim\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Gross Margin\\\",\\\"data\\\":[?]}]}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Comparison of Guidance and Actuals\", \"jir_chart_json_data\": \"{\\\"labels\\\":[\\\"Revenue\\\",\\\"Adjusted Operating Income\\\",\\\"Net Income Attributable to Owners of Parent (Interim)\\\"],\\\"datasets\\\":[{\\\"data\\\":[\\\"1,076,000\uff5e1,064,500\\\",\\\"167,500\uff5e155,000\\\",\\\"199,000\uff5e186,500\\\"]}]}\"}]","ir_related_company":6918,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-147279","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n